A Phase II, Two-Cohort, Open-Label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of MOR00208 Combined With Idelalisib or Venetoclax in Patients With Relapsed or Refractory CLL/SLL Previously Treated With Bruton's Tyrosine Kinase (BTK) Inhibitor

Trial Profile

A Phase II, Two-Cohort, Open-Label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of MOR00208 Combined With Idelalisib or Venetoclax in Patients With Relapsed or Refractory CLL/SLL Previously Treated With Bruton's Tyrosine Kinase (BTK) Inhibitor

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jul 2018

At a glance

  • Drugs MOR 208 (Primary) ; Idelalisib; Venetoclax
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Acronyms COSMOS
  • Sponsors MorphoSys
  • Most Recent Events

    • 20 Jul 2018 Status changed from recruiting to active, no longer recruiting.
    • 17 Jun 2018 Preliminary Safety and Efficacy Results presented at the 23rd Congress of the European Haematology Association.
    • 15 Jun 2018 Results published in the MorphoSys Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top